What You Should Know:
- Exo® (pronounced “echo”), a medical imaging software and devices company, today announced its FDA-cleared cardiac and lung artificial intelligence (AI) applications are now available on Exo Iris™, Exo’s high-performance handheld ultrasound device.
- With affordable, AI-powered medical imaging in a pocket-sized device, caregivers can get to answers immediately to accelerate diagnosis and create new care pathways for heart failure patients at the point of care. As an industry leader in AI, Exo now has FDA 510k clearances on five different applications—cardiac, lung, bladder, hip and thyroid—with plans to double the number of clearances by 2025.
Advancing Heart Failure Diagnosis with AI-Powered Ultrasound
Addressing Healthcare Challenges
The prevalence of heart failure in the United States has surged past 6.7 million individuals, posing significant challenges to both public health and financial sustainability, with healthcare expenditure projected to reach $240 billion by 2030. Despite echocardiography’s efficacy in diagnosing heart failure, its costliness and the need for specialized personnel limit widespread access to medical imaging.
Exo’s latest AI capabilities, exemplified by Exo Iris, offer a breakthrough in simplifying and democratizing access to essential medical imaging, particularly benefiting underserved regions and rural healthcare settings. By harnessing AI-powered handheld ultrasound technology, caregivers can swiftly obtain and interpret cardiac and pulmonary images, expediting diagnosis and treatment irrespective of geographical constraints.
Ensuring Trustworthy AI for Clinical Decision-Making
Exo’s AI algorithms undergo rigorous validation, drawing from a database of over 100,000 real-world point-of-care ultrasound (POCUS) exams. This meticulous validation process ensures the reliability and adaptability of Exo’s AI across diverse patient populations and diagnostic scenarios, empowering caregivers with real-time insights even from suboptimal scans.
Exo’s AI enables clinicians to swiftly differentiate between cardiac and pulmonary conditions, such as COPD and congestive heart failure (CHF), aiding in precise and timely interventions. With Exo’s AI, caregivers can accurately assess cardiac parameters like left ventricle ejection fraction (LVEF) and identify pulmonary edema, facilitating informed clinical decisions in seconds.
Ted Koutouzis, Clinical Instructor in Emergency Medicine at Northwestern Medicine, attests to the transformative impact of Exo’s AI, highlighting its role in enhancing diagnostic efficiency and expanding access to ultrasound technology across diverse healthcare settings.
Expanding Imaging Capabilities in a Portable Ecosystem
Exo continues its commitment to revolutionize medical imaging with a comprehensive ecosystem, featuring Exo Iris, AI solutions, and Exo Works® workflow software. Now available for online purchase, this pocket-sized imaging solution empowers caregivers worldwide with instant access to reliable and affordable medical imaging, aligning with Exo’s vision to modernize healthcare delivery and improve patient outcomes globally.
